BUZZ-Amneal Pharma rises on strong 2025 revenue forecast, Q4 revenue beat

Drugmaker Amneal Pharmaceuticals' AMRX.O shares rise 1.4% to $8.5 premarket

Co forecasts 2025 revenue in the range of $3.0 bln to $3.1 bln, higher than analysts' estimate of $2.9 bln, as per data compiled by LSEG

AMRX posts Q4 revenue of $731 mln vs analysts' estimate of $707.6 mln

Co reports Q4 adj profit of 12 cents/share vs analysts' estimates of 15 cents/share

AMRX expects 2025 adj profit in the range of 65 cents/share to 70 cents/share, analysts on average expect 2025 adj profit of 73 cents/share

Stock has risen 46.8% in the past 12 months